TKPYY Overview
Upcoming Projects (TKPYY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TKPYY)
-
Don’t see a project related to the company you care about? Create your own!
Expired Projects (TKPYY)
Upcoming & Overdue Catalysts (TKPYY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TKPYY)
-
PDUFA Date of April 29th for Ariad's (ARIA) Brigatinib in ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Tickers: TKPYY, ARIA
Occurred on: Apr 28, 2017 -
Amgen (AMGN) Phase 3 ENDEAVOR Data Comparing Kyprolis to Takeada's (TKPYY) Velcade in Relapsed/Refractory Multiple Myeloma
Tickers: AMGN, TKPYY
Occurred on: Feb 28, 2017 -
Takeda's (TKPYY) NINLARO Granted Conditional Approval by European Commission to Treat Multiple Myeloma
Ticker: TKPYY
Occurred on: Nov 24, 2016 -
Seattle Genetics Expects to Complete Enrollment in the Phase 3 ECHELON-2 Trial in Frontline Mature T-cell Lymphoma (MTCL) During 2016
Tickers: SGEN, TKPYY
Occurred on: Nov 08, 2016 -
Takeda's (TKPYY) Ninlaro in Multiple Myeloma Recommended for Approval by European Ad Comm
Ticker: TKPYY
Occurred on: Sep 16, 2016 -
Takeda Initiates Global Phase 3 Clinical Trial (TIDES) of Dengue Vaccine Candidate (TAK-003)
Ticker: TKPYY
Occurred on: Sep 07, 2016 -
Takeda Receives Marketing Authorization in Canada for NINLARO (ixazomib) in Relapsed/Refractory Multiple Myeloma
Ticker: TKPYY
Occurred on: Aug 08, 2016 -
Takeda Submits a New Drug Application for Novel, Oral Proteasome Inhibitor Ixazomib in Japan
Ticker: TKPYY
Occurred on: Jul 04, 2016 -
Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma
Ticker: TKPYY
Occurred on: May 27, 2016 -
Takeda Provides Update on EU Marketing Authorization Application for NINLARO (ixazomib) in Relapsed/Refractory Multiple Myeloma
Ticker: TKPYY
Occurred on: May 27, 2016 -
New business venture focused on generics in Japan to be established in or after April 2016; owned 51% by Teva and 49% by Takeda
Tickers: TEVA, TEVA.TA, TKPYY
Occurred on: Apr 01, 2016 -
Seattle Genetics Announces Commercial and Regulatory Progress under ADCETRIS (Brentuximab Vedotin) Collaboration with Takeda
Tickers: SGEN, TKPYY
Occurred on: Feb 04, 2016 -
Takeda Announces New Drug Application Approval in Japan for a Haemophilus influenzae type b conjugate vaccine, "VAXEM Hib"
Ticker: TKPYY
Occurred on: Jan 22, 2016 -
European Commission Approves Label Variation for ADCETRIS (Brentuximab Vedotin)
Ticker: TKPYY
Occurred on: Jan 22, 2016 -
Takeda Acquires U.S. Biologics Manufacturing Facility from Baxalta for the manufacture of Entyvio (vedolizumab)
Ticker: TKPYY
Occurred on: Jan 06, 2016
Strategic Initiatives (TKPYY)
-
Takeda (TKPYY) Nearing in on Deal to Buy Shire (SHPG) for $64 Billion
Tickers: TKPYY, SHPG
Announcement Date: May 07, 2018 -
Takeda (TKPYY) Agrees to Acquire ARIAD Pharma (ARIA) for $5.2 Billion in Cash
Tickers: ARIA, TKPYY
Announcement Date: Jan 09, 2017 -
Takeda (TKPYY) and Koneksa Health Announce Collaboration to Integrate Digital Health Tools in Clinical Trials
Tickers: TKPYY, Koneksa Health
Announcement Date: Nov 07, 2016 -
Takeda (TKPYY) and Affilogic Agree to Partnership to Develop Central Nervous System Targeted Therapies Based on Affilogic's Nanofitins Platform
Tickers: TKPYY, Affilogic
Announcement Date: Sep 21, 2016
